Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “lung cancer”

Aspects of Quality of Life During Adjuvant Oncological Treatment for Locally Advanced Lung Cancer Which Include Immune Checkpoint Inhibitor.Not Yet Recruiting
NCT07754409N/AUpdated Aug 10, 2026
Sponsor: Göteborg University
Non-Small Cell Carcinoma of Lung
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)Completed
NCT05153239Phase 3Updated Aug 10, 2026
Sponsor: PharmaMar
Relapsed Small Cell Lung Cancer
United States, Australia, Austria, Belgium, Brazil +19 more
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryActive Not Recruiting
NCT06161441Phase 2Updated Aug 10, 2026
Sponsor: Regeneron Pharmaceuticals
Resectable Non-small Cell Lung Cancer
United States, Australia, Chile, France, Georgia +7 more
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLCRecruiting
NCT07754812Phase 4Updated Aug 10, 2026
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
NSCLC (Non-small Cell Lung Cancer)
China
Nitride-Based Raman Biochip for Lung Cancer Diagnosis and MonitoringRecruiting
NCT07755020N/AUpdated Aug 10, 2026
Sponsor: Taichung Veterans General Hospital
Lung Cancer (Diagnosis) · Lung Neoplasms
Taiwan
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLCActive Not Recruiting
NCT07556549N/AUpdated Aug 10, 2026
Sponsor: Pfizer
Non-Small Cell Lung Cancer ALK-positive
China
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR TrialRecruiting
NCT04402788Phase 2, Phase 3Updated Aug 10, 2026
Sponsor: National Cancer Institute (NCI)
Extensive Stage Lung Small Cell Carcinoma
United States
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLCRecruiting
NCT07098988Phase 2Updated Aug 10, 2026
Sponsor: CatalYm GmbH
Metastatic Non-Squamous Non-Small Cell Lung Cancer · Adult Solid Tumor
United States, Germany, Italy, Poland, Romania +2 more
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasCompleted
NCT05262556Phase 1Updated Aug 10, 2026
Sponsor: Amr Mohamed MD
Gastroenteropancreatic Neuroendocrine Tumor · Gastroenteropancreatic Neuroendocrine Neoplasm · Neuroendocrine Carcinoma · Mixed Neuroendocrine-Non Neuroendocrine Neoplasm
United States
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid TumorsActive Not Recruiting
NCT06237881Phase 1, Phase 2Updated Aug 10, 2026
Sponsor: M.D. Anderson Cancer Center
Advanced Solid Tumor · Melanoma · Lung Neoplasms · Head and Neck Neoplasms
United States
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationRecruiting
NCT05789082Phase 1, Phase 2Updated Aug 10, 2026
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +13 more
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 TherapyRecruiting
NCT04892953Phase 2Updated Aug 10, 2026
Sponsor: M.D. Anderson Cancer Center
Stage III Lung Cancer AJCC v8 · Stage III Lung Non-Small Cell Cancer AJCC v7 · Stage IIIA Lung Cancer AJCC v8 · Stage IIIA Lung Non-Small Cell Cancer AJCC v7
United States
SW-682 in Advanced Solid TumorsRecruiting
NCT06251310Phase 1Updated Aug 10, 2026
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Advanced Solid Tumor · Mesothelioma, Malignant
United States
WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System MetastasesActive Not Recruiting
NCT04197934Phase 1Updated Aug 10, 2026
Sponsor: Mayo Clinic
Anaplastic Astrocytoma, IDH-Wildtype · Glioblastoma, IDH-Wildtype · Metastatic Lung Non-Small Cell Carcinoma · Metastatic Malignant Neoplasm in the Central Nervous System
United States
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyRecruiting
NCT04253964Phase 2Updated Aug 10, 2026
Sponsor: Wake Forest University Health Sciences
Nonsmall Cell Lung Cancer · Performance Status
United States
The Impact of COVID-19 on Pulmonary ProceduresRecruiting
NCT05022446N/AUpdated Aug 10, 2026
Sponsor: M.D. Anderson Cancer Center
COVID-19 Infection · Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
United States
Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 ImmunotherapyNot Yet Recruiting
NCT07718737Phase 2, Phase 3Updated Aug 10, 2026
Sponsor: Multitude Therapeutics Inc.
NSCLC (Advanced Non-small Cell Lung Cancer)
United States, Australia
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Recruiting
NCT04585750Phase 1, Phase 2Updated Aug 10, 2026
Sponsor: PMV Pharmaceuticals, Inc
Advanced Solid Tumor · Advanced Malignant Neoplasm · Metastatic Cancer · Metastatic Solid Tumor
United States, Australia, France, Germany, Italy +4 more
Volrustomig Priming Regimens Exploratory Phase II Platform StudyRecruiting
NCT06448754Phase 2Updated Aug 10, 2026
Sponsor: AstraZeneca
Non-small Cell Lung Cancer
United States, Canada, China, France, Georgia +10 more
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsRecruiting
NCT07629960Phase 1, Phase 2Updated Aug 10, 2026
Sponsor: Blueprint Medicines Corporation
Advanced Solid Tumor · Non-Small Cell Lung Cancer · Colorectal Neoplasms · Pancreatic Ductal Adenocarcinoma
United States
Mesothelioma Early Detection by VOCsTerminated
NCT04106973N/AUpdated Aug 10, 2026
Sponsor: Henry Ford Health System
Pleural Mesothelioma · Asbestos Exposure · Pleural Plaque
United States
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D MutationRecruiting
NCT07668752Phase 3Updated Aug 10, 2026
Sponsor: Genfleet Therapeutics (Shanghai) Inc.
KRAS G12D Mutation · NSCLC (Non-small Cell Lung Cancer)
China
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)Recruiting
NCT07541170Phase 3Updated Aug 10, 2026
Sponsor: Hoffmann-La Roche
Non-small Cell Lung Cancer
United States
Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLCNot Yet Recruiting
NCT07754123Phase 3Updated Aug 10, 2026
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced or Metastatic NSCLC
Autoimmune Intervention Mastery Course StudyActive Not Recruiting
NCT05057676NAUpdated Aug 10, 2026
Sponsor: Terry L. Wahls
Multiple Sclerosis · Clinically Isolated Syndrome · Fibromyalgia · Post Acute Sequelae of COVID-19
United States

Previous page Next page